- Home
- PEN vs VTRS Comparison
PEN vs VTRS Comparison
Compare PEN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- VTRS
- Stock Information
- Founded
- PEN 2004
- VTRS 1961
- Country
- PEN United States
- VTRS United States
- Employees
- PEN N/A
- VTRS N/A
- Industry
- PEN Medical/Dental Instruments
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- PEN Health Care
- VTRS Health Care
- Exchange
- PEN Nasdaq
- VTRS Nasdaq
- Market Cap
- PEN 10.9B
- VTRS 12.2B
- IPO Year
- PEN 2015
- VTRS N/A
- Fundamental
- Price
- PEN $289.53
- VTRS $10.47
- Analyst Decision
- PEN Strong Buy
- VTRS Hold
- Analyst Count
- PEN 16
- VTRS 6
- Target Price
- PEN $307.19
- VTRS $11.17
- AVG Volume (30 Days)
- PEN 526.4K
- VTRS 9.9M
- Earning Date
- PEN 11-05-2025
- VTRS 11-06-2025
- Dividend Yield
- PEN N/A
- VTRS 4.59%
- EPS Growth
- PEN 367.34
- VTRS N/A
- EPS
- PEN 4.14
- VTRS N/A
- Revenue
- PEN $1,333,798,000.00
- VTRS $14,124,400,000.00
- Revenue This Year
- PEN $15.52
- VTRS N/A
- Revenue Next Year
- PEN $14.20
- VTRS $1.61
- P/E Ratio
- PEN $69.71
- VTRS N/A
- Revenue Growth
- PEN 14.61
- VTRS N/A
- 52 Week Low
- PEN $221.26
- VTRS $6.85
- 52 Week High
- PEN $310.00
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- PEN 68.64
- VTRS 50.53
- Support Level
- PEN $276.01
- VTRS $10.15
- Resistance Level
- PEN $293.18
- VTRS $10.60
- Average True Range (ATR)
- PEN 8.67
- VTRS 0.38
- MACD
- PEN 2.92
- VTRS -0.05
- Stochastic Oscillator
- PEN 95.40
- VTRS 39.71
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.